
Kathleen V Fitch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2653731/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2015, 2, e52-e63.	4.7	188
2	Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. Journal of Infectious Diseases, 2013, 208, 1737-1746.	4.0	185
3	Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. Aids, 2012, 26, 2409-2412.	2.2	177
4	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). American Heart Journal, 2019, 212, 23-35.	2.7	99
5	Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. Aids, 2006, 20, 1843-1850.	2.2	98
6	RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2873-2882.	3.6	75
7	Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. Aids, 2012, 26, 587-597.	2.2	73
8	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. Topics in Antiviral Medicine, 2015, 23, 146-9.	0.1	70
9	Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 174-184.	2.1	56
10	Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 495-499.	2.1	45
11	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. American Heart Journal, 2019, 212, 1-12.	2.7	43
12	Sustainable food systems and nutrition in the 21st century: a report from the 22nd annual Harvard Nutrition Obesity Symposium. American Journal of Clinical Nutrition, 2022, 115, 18-33.	4.7	43
13	Dysfunctional Subcutaneous Fat With Reduced Dicer and Brown Adipose Tissue Gene Expression in HIV-Infected Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1225-1234.	3.6	39
14	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Network Open, 2021, 4, e2114923.	5.9	38
15	Deiodinase 2 Expression Is Increased in Dorsocervical Fat of Patients with HIV-Associated Lipohypertrophy Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E602-E607.	3.6	29
16	Effects of aging and smoking on carotid intima–media thickness in HIV-infection. Aids, 2013, 27, 49-57.	2.2	26
17	Soluble CD163 Is Associated With Shortened Telomere Length in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 414-418.	2.1	26
18	I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. Open Forum Infectious Diseases, 2018, 5, ofy288.	0.9	25

KATHLEEN V FITCH

#	Article	IF	CITATIONS
19	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clinical Infectious Diseases, 2021, 73, 2009-2022.	5.8	19
20	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab537.	0.9	19
21	Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 421-428.	2.1	18
22	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. Aids, 2019, 33, 229-236.	2.2	18
23	Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. American Journal of Clinical Nutrition, 2011, 94, 1721S-1728S.	4.7	16
24	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine, 2018, 35, 58-66.	6.1	16
25	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. Journal of Infectious Diseases, 2020, 222, 929-939.	4.0	16
26	Anti-Inflammatory Interleukin 10 Inversely Relates to Coronary Atherosclerosis in Persons With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2020, 221, 510-515.	4.0	15
27	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 105-110.	2.1	14
28	Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. Metabolism: Clinical and Experimental, 2009, 58, 608-615.	3.4	13
29	Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. Nutrition and Diabetes, 2019, 9, 6.	3.2	13
30	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. Journal of Infectious Diseases, 2022, 226, 1809-1822.	4.0	11
31	Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. JCI Insight, 2021, 6, .	5.0	10
32	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity, 2020, 28, 749-755.	3.0	9
33	COVID-19 Vaccination Rates in a Global HIV Cohort. Journal of Infectious Diseases, 2022, 225, 603-607.	4.0	8
34	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. Journal of Infectious Diseases, 2020, 222, S31-S40.	4.0	4
35	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 349-359.	2.1	4
36	Relationship of Telomere Length to Fat Redistribution in HIV. Open Forum Infectious Diseases, 2020, 7, ofaa523.	0.9	3

#	Article	IF	CITATIONS
37	An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. Journal of Infectious Diseases, 2020, 222, S41-S51.	4.0	1
38	SUN-052 Low Vitamin D Is Associated with Coronary Atherosclerosis in Women with HIV. Journal of the Endocrine Society, 2019, 3, .	0.2	0